Kedokteran & Kesehatan editorial
Open AccessOA2023
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial
In the NeoPACT phase 2 trial, neoadjuvant carboplatin, docetaxel, and pembrolizumab yielded a 58% pathologic complete response rate and 86% 3-year event-free survival in triple-negative breast cancer, with stromal tumor-infiltrating lymphocytes, PD-L1, DDIR, and TIM signatures independently predicting pCR.
Priyanka Sharma; S. Stecklein; R. Yoder; J. Staley; Kelsey Schwensen; A. O'Dea; L. Nye; D. Satelli; G. Crane; R. Madan; Maura F O'Neil; Jamie L. Wagner; Kelsey E. Larson; Christa R. Balanoff; Lyndsey J. Kilgore; M. Phadnis; A. K. Godwin; R. Salgado; Qamar J. Khan; J. O'Shaughnessyยท JAMA Oncologyยท 2023ยท DOI 10.1001/jamaoncol.2023.5033
The core problem
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and HER2 expression. Standard neoadjuvant chemotherapy, typically anthracycline-based, achieves pathologic complete response (pCR) in approximately 30โ40% of patients, and pCR correlates with improved event-free survival (EFS). The addition of pembrolizumab, an anti-PD-1 antibody, to anthracycline-based chemotherapy has been shown to improve pCR and EFS in TNBC. However, anthracycline-based regimens carry risks of cardiotoxicity and secondary malignancies, and some patients are ineligible due to comorbidities. The efficacy of anthracycline-free chemoimmunotherapy in TNBC remains unassessed. The NeoPACT trial was designed to evaluate the efficacy and safety of carboplatin and docetaxel plus pembrolizumab as an anthracycline-free neoadjuvant regimen, and to explore predictive biomarkers of response.
Innovation
This open-label, single-arm phase 2 clinical trial enrolled 115 female patients with stage I to III TNBC at two sites between September 2018 and January 2022. Eligible patients received neoadjuvant carboplatin (area under the free carboplatin plasma concentration vs time curve of 6) and docetaxel (75 mg/mยฒ) plus pembrolizumab (200 mg) every 21 days for 6 cycles, with myeloid growth factor support. The primary endpoint was pCR, defined as no evidence of invasive tumor in breast and axilla. Secondary endpoints included residual cancer burden (RCB), EFS, toxicity, and immune biomarkers. Pretreatment tumor RNA was subjected to next-generation sequencing to classify specimens as positive or negative for the 44-gene DNA damage immune response (DDIR) signature and the 27-gene tumor immune microenvironment (TIM; DetermaIO) signature using predefined cutoffs. Stromal tumor-infiltrating lymphocytes (sTILs) were evaluated using standard criteria, and PD-L1 expression was assessed by a standard immunohistochemical assay. Biomarker association with pCR was analyzed in multivariable models, and receiver operating characteristic (ROC) curves were used to evaluate predictive performance.
Introduction
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and HER2 expression. Standard neoadjuvant chemotherapy, typically anthracycline-based, achieves pathologic complete response (pCR) in approximately 30โ40% of patients, and pCR correlates with improved event-free survival (EFS). The addition of pembrolizumab, an anti-PD-1 antibody, to anthracycline-based chemotherapy has been shown to improve pCR and EFS in TNBC. However, anthracycline-based regimens carry risks of cardiotoxicity and secondary malignancies, and some patients are ineligible due to comorbidities. The efficacy of anthracycline-free chemoimmunotherapy in TNBC remains unassessed. The NeoPACT trial was designed to evaluate the efficacy and safety of carboplatin and docetaxel plus pembrolizumab as an anthracycline-free neoadjuvant regimen, and to explore predictive biomarkers of response.
Why it matters
The NeoPACT trial demonstrates that an anthracycline-free neoadjuvant regimen of carboplatin, docetaxel, and pembrolizumab yields encouraging pCR and 3-year EFS in TNBC, with a manageable toxicity profile. The pCR rate of 58% compares favorably with historical rates for anthracycline-based chemotherapy alone and is within the range reported for anthracycline-based chemoimmunotherapy, suggesting that anthracyclines may be omitted without compromising efficacy. The strong association between pCR and EFS (98% vs 68% at 3 years) reinforces pCR as a surrogate endpoint. The independent predictive value of sTILs, PD-L1, DDIR, and TIM highlights the role of immune enrichment in response to chemoimmunotherapy. The DDIR signature, which reflects DNA damage repair defects and immune activation, and the TIM signature, which captures the tumor immune microenvironment, provide complementary information. These findings support further evaluation of this regimen as a chemotherapy de-escalation strategy in randomized studies and offer an alternative for patients ineligible for anthracyclines. Limitations include the single-arm design, lack of a comparator, and the exploratory nature of biomarker analyses. Future randomized trials should compare this regimen with anthracycline-based chemoimmunotherapy and validate the biomarkers prospectively.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ